Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome
Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced today that it has finalized its Phase 3 EMPEROR study design…
Heart Failure Program and Leadership Change Announced by RyCarma
Heart Failure Program and Leadership Change Announced by RyCarma RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma, is a clinical-stage biotech company focused on developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Today, the company announced its…
Announces REZZAYO® Approval in Spain for Invasive Candidiasis Treatment by Mundipharma
Announces REZZAYO® Approval in Spain for Invasive Candidiasis Treatment by Mundipharma Mundipharma announces today that Spain’s Ministry of Health has approved reimbursement for REZZAYO® (rezafungin acetate) as a treatment for invasive candidiasis in adults. This announcement follows the European Commission’s…
Arcturus Begins Phase 2 Dosing for CF and OTC Deficiency
Arcturus Begins Phase 2 Dosing for CF and OTC Deficiency Arcturus Therapeutics Holdings Inc., a pioneering company in mRNA medicine, announced that it has initiated Phase 2 multiple ascending dose studies for two major conditions—cystic fibrosis (CF) and ornithine transcarbamylase…
Collaboration Between Team Gleason and Synchron Expands BCI Efforts
Collaboration Between Team Gleason and Synchron Expands BCI Efforts Synchron, a leading brain-computer interface (BCI) company, and Team Gleason, a foundation focused on enhancing the lives of individuals living with Amyotrophic Lateral Sclerosis (ALS), have expanded their partnership to promote…
NanoVibronix Completes UroShield® Pilot Study at University of Michigan
NanoVibronix Completes UroShield® Pilot Study at University of Michigan NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company specializing in portable ultrasonic therapeutic devices such as UroShield®, PainShield®, and WoundShield®, has announced the successful completion of the first phase of a…
Conference Preview: Avenacy Updates 2025 Strategy Ahead of J.P. Morgan Healthcare Event
Conference Preview: Avenacy Updates 2025 Strategy Ahead of J.P. Morgan Healthcare Event Avenacy, a specialty pharmaceutical company focused on providing critical injectable medications, has shared updates regarding its recent business achievements, financial performance for 2024, and strategic priorities for 2025.…
FDA Grants Fast Track to Star Therapeutics for VGA039 in VWD
FDA Grants Fast Track to Star Therapeutics for VGA039 in VWD Star Therapeutics, a clinical-stage biotechnology company focused on developing cutting-edge antibodies, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VGA039, an…
UK Grants Conditional Approval for Amgen’s Tarlatamab in SCLC
UK Grants Conditional Approval for Amgen’s Tarlatamab in SCLC Amgen has announced that its bispecific antibody, IMDYLLTRA® (tarlatamab), has received conditional marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adult patients with…
Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences
Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences Castle Biosciences, Inc. (Nasdaq: CSTL), a leading company in providing innovative tests to guide patient care, has announced that its TissueCypher® Barrett’s Esophagus test has been approved by the New…
Pipeline Drives Orbis Medicines to Raise EUR 90 Million in Series A Funding
Pipeline Drives Orbis Medicines to Raise EUR 90 Million in Series A Funding Orbis Medicines, a leader in oral macrocycle drug discovery, has successfully closed a EUR 90 million Series A funding round, bringing the company’s total capital raised to…
Appoints Giancarlo Benelli as Head of Europe at BeiGene
Appoints Giancarlo Benelli as Head of Europe at BeiGene BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines Ltd., appoints Giancarlo Benelli as Senior Vice President and Head of Europe, effective…